Food Advisory Committee Meeting December 16 and 17, 2014 Questions to the Committee Suzanne C. Fitzpatrick, PhD, DABT Senior Advisory for Toxicology Center.

Slides:



Advertisements
Similar presentations
Perspectives from EPA’s Endocrine Disruptor Screening Program
Advertisements

Office of New Animal Drug Evaluation Laura L. Hungerford, DVM, MPH, PhD Senior Advisor, Science and Policy, ONADE Professor, University of Maryland School.
Food Advisory Committee Meeting Risk assessments and susceptible life stages and populations December 16, 2014 Rachel Osterman Associate Chief Counsel,
Wrap-Up and Potential Future Actions Mary J. Bartholomew, Mathematical Statistician Center for Veterinary Medicine Center for Veterinary Medicine at the.
Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.
Trichloroethylene (TCE) Toxicity Values Update Waste Site Cleanup Advisory Committee Meeting March 27, 2014 C. Mark Smith Ph.D., M.S. Deputy Director Office.
Regulatory Toxicology James Swenberg, D.V.M., Ph.D.
Carcinogen Classification Criteria Patricia Richter Ph.D., DABT Tobacco Products Scientific Advisory Committee June 8, 2010.
Guidelines for Carcinogen Risk Assessment and Supplemental Guidance for Assessing Cancer Risks from Early-Life Exposures March 29, 2005 Hugh A. Barton,
CONFERENCE ON “ FOOD ADDITIVES : SAFETY IN USE AND CONSUMER CONCERNS“ JOMO KENYATTA UNIVERSITY OF AGRICULTURE AND TECHNOLOGY NAIROBI, 24 JUNE 2014.
Lessons Learned in Initiating and Conducting Risk Assessments within a Risk Analysis Framework: A FDA/CFSAN Approach Robert Buchanan DHHS Food and Drug.
Cumulative Risk Assessment for Pesticide Regulation: A Risk Characterization Challenge Mary A. Fox, PhD, MPH Linda C. Abbott, PhD USDA Office of Risk Assessment.
11111 Beth M. Hassett-Sipple, US EPA/OAQPS EPA/WESTAR Residential Wood Smoke Workshop March 1, 2011 Salt Lake City, UT National Ambient Air Quality Standards.
What Do Toxicologists Do?
Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.
Health and Safety Executive Health and Safety Executive Improving the efficiency of the regulatory process Rob Mason Head of Regulatory Policy Chemicals.
Neonatal/Juvenile Animal Safety Studies Kenneth L. Hastings, Dr.P.H., D.A.B.T. Office of New Drugs, CDER.
Effectiveness Evaluation for Therapeutic Drugs for Non-Food Animals
Biomedical research methods. What are biomedical research methods? An integrated approach using chemical, mathematical and computer simulations, in vitro.
FAO/WHO CODEX TRAINING PACKAGE
Animal Feed GRAS Notifications Geoffrey K. Wong, M.S. Division of Animal Feeds Center for Veterinary Medicine Pet Food Institute Pet Food Institute October.
June 16-19, USEPA Cancer Guidelines: Mode of Carcinogenic Action 1 ICABR – Impacts of the Bioeconomy on Agricultural Sustainability, the Environment.
Codex Guidelines for the Application of HACCP
Internal Auditing and Outsourcing
Environmental Risk Analysis
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
1 Mid-Term Review of the Hyogo Framework for Action Roadmap to Disaster Risk Reduction in the Americas & HFA Mid-Term Review.
Evidence-Based Public Health Nancy Allee, MLS, MPH University of Michigan November 6, 2004.
Furan in Food Summary and Charge to the FAC and SCNT Terry C. Troxell, Ph.D. Director Office of Plant and Dairy Foods FDA Center for Food Safety and Applied.
Health Impact Assessment for Healthy Places: A Guide for Planning and Public Health Module 6: Evaluation Goal: The goal of this module is to understand.
Major Components of FDA’s Action Plan for Acrylamide Richard Canady, PhD DABT US Food and Drug Administration Center for Food Safety and Applied Nutrition.
Module 3 Risk Analysis and its Components. Risk Analysis ● WTO SPS agreement puts emphasis on sound science ● Risk analysis = integrated mechanism to.
Food Quality Protection Act of 1996 by: Bjorn Bookser period 2.
FAO/WHO Codex Training Package Module 4.3 FAO/WHO CODEX TRAINING PACKAGE SECTION FOUR – SCIENTIFIC BASIS FOR CODEX WORK 4.3 What is JECFA?
Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April Quantitative risk analysis using exposure-response.
Background on Furan in Foods Nega Beru, Ph.D. Director, Division of Plant Product Safety Office of Plant and Dairy Foods Center for Food and Applied Nutrition.
What is a Public Health Assessment? “The evaluation of data and information on the release of harmful substances into the environment in order to assess.
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
(Slide 1 of 22) Response to the National Vaccine Advisory Committee Recommendations on the Immunization Safety Office Scientific Agenda Frank DeStefano,
WHO GUIDANCE FOR THE DEVELOPMENT OF EVIDENCE-BASED VACCINE RELATED RECOMMENDATIONS August 2011.
1 The Future Role of the Food and Veterinary Office M.C. Gaynor, Director, FVO EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL Directorate.
Systematic Review: Interpreting Results and Identifying Gaps October 17, 2012.
IAEA International Atomic Energy Agency Methodology and Responsibilities for Periodic Safety Review for Research Reactors William Kennedy Research Reactor.
Chapter 15.3 Risk Assessment 2002 WHO report: “Focusing on risks to health is the key to preventing disease and injury.” risk assessment—process of evaluating.
Air Toxics Risk Assessment: Traditional versus New Approaches Mark Saperstein BP Product Stewardship Group.
DoD Comments to NRC Committee on Improvements to EPA Risk Analysis Yvonne P. Walker, MS, MSE, CIH Director, Environmental Programs Navy Environmental Health.
International Atomic Energy Agency Regulatory Review of Safety Cases for Radioactive Waste Disposal Facilities David G Bennett 7 April 2014.
Overview FDA Food Safety Modernization Act Section 104
Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,
Questions to Committee about Potential Cancer Risk with Use of Topical Immunosuppressants (Calcineurin Inhibitors) Question 1: Messages about Risk A. Based.
Bioequivalence Criteria Research Plan Stella G. Machado, Ph.D. Office of Biostatistics and the Replicate Design Technical Committee Advisory Committee.
Perspective on the current state-of-knowledge of mode of action as it relates to the dose response assessment of cancer and noncancer toxicity Jennifer.
1 Harmful/Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Tobacco Product Constituents Subcommittee Meeting July 7, 2010 Corinne.
© 2011 Michigan State University and United Nations Industrial Development Organization, original at CC-BY-SA HACCP Principle.
1. Consumers, Health, Agriculture and Food Executive Agency Risk assessment with regard to food and feed safety Risk analysis Why risk assessment in the.
Abstract A step-wise or ‘tiered’ approach has been used as a rational procedure to conduct environmental risk assessments in many disciplines. The Technical.
Dr Karl Davis Consultant Geriatrician. Public Health Wales All the frameworks highlighted the following six areas as key priorities (although there is.
Organization and Implementation of a National Regulatory Program for the Control of Radiation Sources Program Performance Criteria.
 Planning an audit of cost statements, records and other related documents is considered necessary to ensure achievement of audit objectives with available.
IADSA SCIENTIFIC FORUM, MOSCOW, June 2009 The European Union Perspective on Risk/Benefit Professor Dr. Arpad Somogyi Berlin - Brussels - Budapest.
Systematic review of the potential adverse effects of caffeine consumption in healthy adults, pregnant women, adolescents, and children: Cardiovascular.
The US Climate Health Assessment
Regulatory Considerations for Approval: FDA perspective
Evaluating Cumulative Impacts: The Value of Epidemiology
FDA’s IDE Decisions and Communications
IND Review Process Seoul National University
Allen Chan U.S. Government Accountability Office October 2, 2018
Evaluating Cumulative Impacts: The Value of Epidemiology
Regulatory Perspective of the Use of EHRs in RCTs
VICH GL 54, Studies to evaluate the safety of residues of veterinary drugs in human food: General approach to establish an Acute Reference Dose (ARfD)
Presentation transcript:

Food Advisory Committee Meeting December 16 and 17, 2014 Questions to the Committee Suzanne C. Fitzpatrick, PhD, DABT Senior Advisory for Toxicology Center for Food Safety & Applied Nutrition

Background In administering the pertinent provisions of the Federal Food, Drug, and Cosmetic Act, the Foods Program’s Center for Food Safety and Applied Nutrition and Center for Veterinary Medicine need to ensure that their chemical assessments and any resulting risk management decisions protect all affected human populations to the extent feasible and consistent with the applicable statutory standard. The Foods Program requests guidance from its Food Advisory Committee on how to integrate scientific considerations for susceptible populations into its risk assessment procedures and methodologies, including under what conditions a separate risk assessment should be conducted.

1. When conducting a risk assessment: – What are the most important susceptibility factors to consider when determining whether a certain segment of a population could be considered more (or less) susceptible to the effects of a chemical? – What data and level of confidence in the data are needed to initiate the development of a separate risk assessment for the subpopulation(s) determined to be susceptible? Is an epidemiologic study or animal bioassay that reports quantitative results showing an association between exposure and effects for susceptible individuals sufficient? What additional types of data should be considered? How should data that cannot be quantified be considered and weighted? Should different types of data be weighted differently?

2 a. Are these appropriate questions to be considered in the problem formulation, planning, and scoping phases? Are there specific subpopulations or life stages of particular concern? Are some exposure routes or durations of particular concern to specific populations? How will exposures of the populations of interest be estimated? What are the quality and quantity of data available to identify whether or not subpopulations are disproportionately susceptible? How can the assessment be used to support decisions regarding susceptible populations? What additional questions should be considered?

2 b. What additional areas of expertise should be considered? Examples of expertise needed on a risk assessment team could include: Toxicologists Epidemiologists Physicians Exposure assessors

3. What are the mechanisms to ensure that relevant outcomes are identified, considered, and prioritized for different susceptible populations? For example- NRC (2014b), in its review of EPA’s Integrated Risk Information System, recommends conducting a systematic review to identify, evaluate, and integrate evidence from the literature regarding those outcomes that are of greatest significance, including for susceptible populations.

4.How do differences in outcome latency and outcome development influence consideration of susceptibility factors in assessing whether a particular subpopulation is differentially susceptible? What types of studies are needed to address such differences? For example, there can be latent effects that do not present clinically for years to decades after exposure, such as carcinogenesis, cognitive deficits, and endocrine disruption. Other effects can be transient, such as some peripheral neuropathies.

5. For potential departures from use of the established intraspecies factor of 10 in risk assessments, what criteria need to be considered? There has been considerable debate surrounding the use of this default uncertainty factor and its adequacy in accounting for susceptible populations. Efforts to evaluate the scientific basis of this uncertainty factor have focused on evaluating inter-individual variability in healthy adult populations or by considering the sensitivity of specific subsets of the population thought to be particularly susceptible (Martin et al. 2013).

6.Should FDA consider adopting defined life stages into recommendations it may develop on susceptible subpopulations? If so, what relevant issues should be considered in defining these life stages? What should these stages be?